Status:
UNKNOWN
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
Lead Sponsor:
National Liver Institute, Egypt
Collaborating Sponsors:
Future pharmaceutical industries
Conditions:
Helicobacter Pylori
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive...
Detailed Description
This will be randomized, parallel group, comparative open-label study that will be conducted to evaluate the efficacy and tolerability of a four-drug regimen (modified LOAD regimen) in eradicating HP....
Eligibility Criteria
Inclusion
- Patients presented with dyspepsia for more than one month with positive H. pylori antigen test in stool
Exclusion
- Treatment with proton pump inhibitors, bismuth, H2 receptor antagonist, or sucralfate within the two weeks before study entry, recent use of antibiotics (within one month), allergy to any of the study drugs, active bleeding, gastric surgery, pregnancy, any current malignancy.
Key Trial Info
Start Date :
October 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05184491
Start Date
October 15 2021
End Date
March 15 2022
Last Update
January 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Liver institute - Menoufia University
Shibīn al Kawm, Menoufia, Egypt